pHLIP-Mediated Translocation of Membrane-Impermeable Molecules into Cells

Chemistry and Biology

Volumn 16, Issue 7, 2009, Pages 754-762

  Thévenin, Damien ^a   An, Ming ^a   Engelman, Donald M ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

CELLBIO; CHEMBIO

Indexed keywords

CYCLOPEPTIDE;

ARTICLE; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; FLUORESCENCE MICROSCOPY; HELA CELL; HUMAN; METHODOLOGY; NEOPLASM; PATHOLOGY; PH; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEMS; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, FLUORESCENCE; NEOPLASMS; PEPTIDES, CYCLIC; PROTEIN STRUCTURE, SECONDARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67651095995     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2009.06.006     Document Type: Article

References (52)

1. Abramoff M.D., Magelhaes P.J., and Ram S.J. Image processing with ImageJ. Biophotonics International 11 (2004) 36-42
2. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
3. Andreev O.A., Dupuy A.D., Segala M., Sandugu S., Serra D.A., Chichester C.O., Engelman D.M., and Reshetnyak Y.K. Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc. Natl. Acad. Sci. USA 104 (2007) 7893-7898
4. Bild A.H., Potti A., and Nevins J.R. Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer 6 (2006) 735-741
5. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., Joshi M.B., Harpole D., Lancaster J.M., Berchuck A., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (2006) 353-357
6. Burstein E.A., Vedenkina N.S., and Ivkova M.N. Fluorescence and the location of tryptophan residues in protein molecules. Photochem. Photobiol. 18 (1973) 263-279
7. Cairns R., Papandreou I., and Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res. 4 (2006) 61-70
8. Derossi D., Joliot A.H., Chassaing G., and Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269 (1994) 10444-10450
9. Dharap S.S., and Minko T. Targeted proapoptotic LHRH-BH3 peptide. Pharm. Res. 20 (2003) 889-896
10. Dharap S.S., Qiu B., Williams G.C., Sinko P., Stein S., and Minko T. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J. Control. Release 91 (2003) 61-73
11. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6 (2006) 688-701
12. Elmquist A., Lindgren M., Bartfai T., and Langel U. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp. Cell Res. 269 (2001) 237-244
13. Fennelly D. Dose intensity in advanced ovarian cancer: have we answered the question?. Clin. Cancer Res. 1 (1995) 575-582
14. Fenske D.B., and Cullis P.R. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol. 391 (2005) 7-40
15. Fischer R., Fotin-Mleczek M., Hufnagel H., and Brock R. Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptides. ChemBioChem 6 (2005) 2126-2142
16. Futaki S. Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. Biopolymers 84 (2006) 241-249
17. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., and Sugiura Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276 (2001) 5836-5840
18. Gatenby R.A., and Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 4 (2004) 891-899
19. Gerweck L.E., and Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 56 (1996) 1194-1198
20. Haag R., and Kratz F. Polymer therapeutics: concepts and applications. Angew. Chem. Int. Ed. Engl. 45 (2006) 1198-1215
21. Hanrahan E.O., Hennessy B.T., and Valero V. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin. Pharmacother. 6 (2005) 1477-1491
22. Helmlinger G., Sckell A., Dellian M., Forbes N.S., and Jain R.K. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res. 8 (2002) 1284-1291
23. Henriques S.T., Melo M.N., and Castanho M.A.R.B. Cell-penetrating peptides and antimicrobial peptides: how different are they?. Biochem. J. 399 (2006) 1-7
24. Hunt J.F., Earnest T.N., Bousché O., Kalghatgi K., Reilly K., Horváth C., Rothschild K.J., and Engelman D.M. A biophysical study of integral membrane protein folding. Biochemistry 36 (1997) 15156-15176
25. Junior A.D., Mota L.G., Nunan E.A., Wainstein A.J., Wainstein A.P., Leal A.S., Cardoso V.N., and De Oliveira M.C. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. Life Sci. 80 (2007) 659-664
26. Kim J.W., and Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66 (2006) 8927-8930
27. Lem W.J., and Wayman M. Decomposition of aqueous dithionite. Part I. Kinetics of decomposition of aqueous sodium dithionite. Can. J. Chem. 48 (1970) 776-781
28. Li W., Nicol F., and Szoka Jr. F.C. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv. Drug Deliv. Rev. 56 (2004) 967-985
29. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
30. Maeda H., Sawa T., and Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 74 (2001) 47-61
31. Martin M.E., and Rice K.G. Peptide-guided gene delivery. AAPS J. 9 (2007) E18-E29
32. McIntyre J.C., and Sleight R.G. Fluorescence assay for phospholipid membrane asymmetry. Biochemistry 30 (1991) 11819-11827
33. Minko T., Dharap S.S., Pakunlu R.I., and Wang Y. Molecular targeting of drug delivery systems to cancer. Curr. Drug Targets 5 (2004) 389-406
34. Mrkvan T., Sirova M., Etrych T., Chytil P., Strohalm J., Plocova D., Ulbrich K., and Rihova B. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity. J. Control. Release 110 (2005) 119-129
35. Murphy N., Millar E., and Lee C.S. Gene expression profiling in breast cancer: towards individualising patient management. Pathology 37 (2005) 271-277
36. Reshetnyak Y.K., Andreev O.A., Lehnert U., and Engelman D.M. Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix. Proc. Natl. Acad. Sci. USA 103 (2006) 6460-6465
37. Reshetnyak Y.K., Segala M., Andreev O.A., and Engelman D.M. A monomeric membrane peptide that lives in three worlds: in solution, attached to, and inserted across lipid bilayers. Biophys. J. 93 (2007) 2363-2372
38. Reshetnyak Y.K., Andreev O.A., Segala M., Markin V.S., and Engelman D.M. Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer membrane. Proc. Natl. Acad. Sci. USA 105 (2008) 15340-15345
39. Ross R.W., and Small E.J. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J. Urol. 167 (2002) 1952-1956
40. Sehouli J., Stengel D., Elling D., Ortmann O., Blohmer J., Riess H., Lichtenegger W., and Ovarian Cancer Study Group of the Nordostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. Gynecol. Oncol. 85 (2002) 321-326
41. Sethuraman V.A., Na K., and Bae Y.H. pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. Biomacromolecules 7 (2006) 64-70
42. Stegmann T. Membrane fusion mechanisms: the influenza hemagglutinin paradigm and its implications for intracellular fusion. Traffic 1 (2000) 598-604
43. Stewart J.C. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104 (1980) 10-14
44. Swietach P., Vaughan-Jones R.D., and Harris A.L. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 26 (2007) 299-310
45. Tang J., and Gai F. Dissecting the membrane binding and insertion kinetics of a pHLIP peptide. Biochemistry 47 (2008) 8250-8252
46. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9 (2007) E128-E147
47. Torchilin V.P. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev. 60 (2008) 548-558
48. Vives E., Brodin P., and Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997) 16010-16017
49. Wagstaff K.M., and Jans D.A. Protein transduction: cell penetrating peptides and their therapeutic applications. Curr. Med. Chem. 13 (2006) 1371-1387
50. Wayman M., and Lem W.J. Decomposition of aqueous dithionite. Part II. A reaction mchanism for decomposition of aqueous sodium dithionite. Can. J. Chem. 48 (1970) 782-787
51. Yezhelyev M.V., Gao X., Xing Y., Al-Hajj A., Nie S.M., and O'Regan R.M. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 7 (2006) 657-667
52. Zoonens M., Reshetnyak Y.K., and Engelman D.M. Bilayer interactions of pHLIP, a peptide that can deliver drugs and target tumors. Biophys. J. 95 (2008) 225-235